GSK must pay AstraZeneca royalties on Zejula, UK court rules
GSK must pay royalties to AstraZeneca on total sales of its ovarian cancer drug Zejula, a UK court ruled on Wednesday.
The case traces back to a licensing deal Tesaro struck with AstraZeneca back in 2012 — years before it was snapped up by GSK for $5.1 billion — which led to the approval of Zejula in 2017 for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The PARP inhibitor has picked up a handful of label expansions, including as a first-line maintenance therapy for advanced ovarian cancer and as a fourth-line treatment, though that indication has since been pulled.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
